Prediction of pharmacokinetics of antibiotics in patients with end-stage renal disease

被引:3
|
作者
Tajima, Naoyuki
Nagashima, Satoru
Uematsu, Toshihiko
Torii, Hideki
Tajima, Masami
Hishida, Akira
Naganuma, Hideo
机构
[1] Sankyo Co Ltd, Clin Pharmacol & Biostat Dept, Shinagawa Ku, Tokyo 1408710, Japan
[2] Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Shinagawa Ku, Tokyo 1408710, Japan
[3] Shitoro Clin, Hamamatsu, Shizuoka 4328067, Japan
[4] Hamamatsu Univ Sch Med, Dept Med 1, Hamamatsu, Shizuoka 4313192, Japan
关键词
prediction; pharmacokinetics; hemodialysis; end-stage renal disease (ESRD); antibiotic;
D O I
10.1248/bpb.29.1454
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A novel and convenient method to predict the pharmacokinetics of several kinds of antibiotic agents in patients with end-stage renal disease (ESRD) was examined based on the in vitro extraction ratios and pharmacokinetic parameters in healthy volunteers. The dializability of 17 antibiotic agents in 4% human serum albumin solution were determined using a high-performance hemodialytic membrane for clinical use. We assumed that the off-hemodialysis clearance approximated the non-renal clearance, while the on-hemodialysis clearance was considered to be sum of the off-hemodialysis clearance and the hemodialytic clearance. The estimated on- and off-hemodialysis clearances were compared with the ones observed in ESRD patients. In order to confirm the method prospectively, an in vivo pharmacokinetic study was performed in dogs with mercury chloride-induced experimental renal failure. The in vitro extraction ratios of 9 beta-lactams were broadly ranged from 10.9 to 75.6% depending on their physicochemical properties. In contrast, those of the other antibiotics were consistent with their chemical classes: 60.5-63.2% for fluoroquinolone, 48.8-51.1% for aminoglycoside and 18.7-25.6% for glycopeptide. Both the estimated on- and off-hemodialysis clearances of the 17 antibiotics coincided well with the observed values in the literature, regardless of their physicochemical and pharmacokinetic properties. The validity and applicability of this method to three cefems, cefmetazole, cefotaxime and cefoperazone, was prospectively confirmed in the animal study. In conclusion, this new method enables the prediction of the on- and off-hemodialysis clearances of several kinds of antibiotics in ESRD patients from minimal information of their pharmacokinetics in healthy subjects and their in vitro dializability.
引用
收藏
页码:1454 / 1459
页数:6
相关论文
共 50 条
  • [21] Venetoclax pharmacokinetics in participants with end-stage renal disease undergoing haemodialysis
    Noorani, Behnam
    Menon, Rajeev M.
    Chen, Xin
    Marsh, Kennan C.
    Huang, Weize
    Gupta, Shelly
    Dobkowska, Edyta
    Marbury, Thomas
    Salem, Ahmed Hamed
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (03) : 748 - 758
  • [22] Pharmacokinetics of Enarodustat in Non-Japanese and Japanese Healthy Subjects and in Patients With End-Stage Renal Disease on Hemodialysis
    Pai, Sudhakar M.
    Kambhampati, Siva Rama Prasad
    Naruhashi, Shinya
    Yamada, Hiroyuki
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (07): : 683 - 690
  • [23] Safety and Pharmacokinetics of Subcutaneously Administered Rilonacept in Patients With Well-Controlled End-Stage Renal Disease (ESRD)
    Radin, Allen
    Marbury, Thomas
    Osgood, Greg
    Belomestnov, Pavel
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (07) : 835 - 841
  • [24] End-stage renal disease in patients with rheumatoid arthritis
    Paudyal, Sunita
    Yang, Frances M.
    Rice, Christopher
    Chen, Chen-Chun
    Skelton, Michael
    Bethel, Monique
    Brown, Shilpa
    Nahman, Norris Stanley, Jr.
    Carbone, Laura
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017, 46 (04) : 418 - 422
  • [25] Pulmonary hypertension in patients with end-stage renal disease
    Yigla, M
    Nakhoul, F
    Sabag, A
    Tov, N
    Gorevich, B
    Abassi, Z
    Reisner, SA
    CHEST, 2003, 123 (05) : 1577 - 1582
  • [26] Quality of life in end-stage renal disease patients
    Valderrábano, F
    Jofre, R
    López-Gómez, JM
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (03) : 443 - 464
  • [27] Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease
    Small, D. S.
    Wrishko, R. E.
    Ernest, C. S., II
    Ni, L.
    Winters, K. J.
    Farid, N. A.
    Li, Y. G.
    Brandt, J. T.
    Salazar, D. E.
    Borel, A. G.
    Kles, K. A.
    Payne, C. D.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2009, 34 (05) : 585 - 594
  • [28] Perioperative Management of Patients With End-Stage Renal Disease
    Kanda, Hirotsugu
    Hirasaki, Yuji
    Iida, Takafumi
    Kanao-Kanda, Megumi
    Toyama, Yuki
    Chiba, Takashi
    Kunisawa, Takayuki
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2017, 31 (06) : 2251 - 2267
  • [29] Acute Appendicitis in Patients with End-Stage Renal Disease
    Chao, Pei-Wen
    Ou, Shuo-Ming
    Chen, Yung-Tai
    Lee, Yi-Jung
    Wang, Feng-Ming
    Liu, Chia-Jen
    Yang, Wu-Chang
    Chen, Tzeng-Ji
    Chen, Tzen-Wen
    Li, Szu-Yuan
    JOURNAL OF GASTROINTESTINAL SURGERY, 2012, 16 (10) : 1940 - 1946
  • [30] Deferasirox in thalassemia patients with end-stage renal disease
    Beydoun, Hassan G.
    Saliba, Antoine N.
    Taher, Ali T.
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (10) : E456 - E457